The article is written in good English and discusses an important gap in the field.
I hope the comments below are helpful: 1) Description of overall study design. The writing is clear, but it may help the reader to add a single sentence at the start of the methods (line 82) stating that the study comprised three phases: (1) Literature review; (2) Discussion Groups and (3) Delphi consultation.
2) Discussion around different disease stages. The study identifies an outcome set for newly diagnosed patients only (line 149). The identified outcome measures have not therefore been appraised as suitable for relapsed patients or those in the palliative phase. It would be clearer for the reader in the article title reflected this. I may also be helpful to discuss this further in the study limitations. The median survival in myeloma now extends to 5-10 years in some groups, so an outcome set covering all disease stages would a valuable avenue for future work.
3) Details of literature review and discussion groups. The authors report that they carried out a literature review to 'identify clinical outcomes and PROs…to steer five discussion groups' (line 88).
There is little detail in the results about the PROs identified in the literature, and how the discussion groups then reviewed and selected tools from those identified. The authors mention in their Discussion that more than 70 instruments were identified and 'the biggest challenge was to choose from the huge variety of variables, especially for PROMS' (line 252). This would perhaps sit better in the results alongside more detail of how this challenge was met. The choice of variables and instruments would appear to be at the heart of what this article tries to do, yet there is little detail on how this was achieved. How were the 70 instruments appraised? Who appraised them -the authors or the study participants? Did the discussion groups view all the instruments or did the authors give a selection for them to review?
4) The results state that 'The healthcare professionals participating in the discussion groups recommended the EORTC-QLQ-C30 as the PROM covering most of these variables' (line 200). This view was then used to design the Delphi questionnaire, yet it is noteworthy that only 4 haematologists and 4 pharmacists took part in these groups (line 100). It is hard to interpret the relatability of this recommendation without more detail on the methods used to support these 8 professionals in selecting the best PROM for appraisal in the Delphi phase. A clear description is included of why these professionals chose to exclude the EORTC MY20 myeloma module (line 205), but there are other myeloma-specific tools that were not mentioned: I hope you find these comments helpful.
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GENERAL COMMENTS
The authors have made a significant effort in order to propose a standardized set of measurements for the assessment of treatment outcomes of patients with MM. There are several vague points when such an effort is based on consensus rather than on solid data but as the authors state this is a first and important step. Another important aspect of this effort is that it has to be continued in order to collect the data and then, even more difficult in my opinion , to evaluate the data and the results and implement in the clinical practice. I have some minor comments for the authors "Due to the high mortality rate and short life expectancy of patients with MM, the health professionals who participated in the discussions group pre-selected the following variables: overall survival (OS), progression-free survival (PFS), minimal residual disease (MRD), and response criteria (RC)."
These are expected measures and already required by the health authorities , for drug approval. R1Q3: I may also be helpful to discuss this further in the study limitations. The median survival in myeloma now extends to 5-10 years in some groups, so an outcome set covering all disease stages would a valuable avenue for future work.
R1A3: As the reviewer adequately suggested, the limitation of the standard set has been discussed, since it is a target for newly diagnosed patients.
Line 305 (Discussion) "Moreover, new therapies have risen the mean overall survival to 6-7 years [4] . Thus, develop an outcome set covering all disease stages, and not only those targeting newly diagnosed patients, would be interesting for future work." R1Q4: Details of literature review and discussion groups. The authors report that they carried out a literature review to 'identify clinical outcomes and PROs…to steer five discussion groups' (line 88).
There is little detail in the results about the PROs identified in the literature, and how the discussion groups then reviewed and selected tools from those identified. The authors mention in their Discussion that more than 70 instruments were identified and 'the biggest challenge was to choose from the huge variety of variables, especially for PROMS' (line 252). This would perhaps sit better in the results alongside more detail of how this challenge was met.
R1A4: The sentence has been moved to "Results". In addition, results about the process of selection of variables and instruments have been detailed.
Line 151 (Results) "We performed an in-depth literature search identifying almost 40 outcomes and more than 70 instruments. In fact, the biggest challenge was to choose from the huge variety of variables, especially for PROMs. The whole outcomes, clinical instruments, and 30 PROMs were preselected by the scientific committee. From those, 18 follow-up variables and 21 instruments were included in Delphi consultation after deliberation in discussion groups. The standard set includes 15 follow-up variables and 18 measure instruments."
R1Q5: The choice of variables and instruments would appear to be at the heart of what this article tries to do, yet there is little detail on how this was achieved. How were the 70 instruments appraised? Who appraised them -the authors or the study participants? Did the discussion groups view all the instruments or did the authors give a selection for them to review?
R1A5: All these questions have been clarified through the Methods section.
Line 94 (Methods: literature review) "Presetting of instruments was done by the scientific committee considering the availability of a validated version in the Spanish population, the level of evidence of the reviewed studies (Oxford CEBM Levels of Evidence) and their agreement on its utilization (according to bibliography references). Consensus of ¾ was necessary for inclusion."
Line 104 (Methods: Discussion groups) "Outcomes and instruments were appraised according to their use in the Spanish routine clinical practice (expert opinion), the simplicity of completion, and the grade of disease's impact on the variables from patient's view."
And line 111: "Variables and instruments that achieved consensus for their inclusion (¾) and those controversial (½), were included in Delphi consultation" R1Q6: The results state that 'The healthcare professionals participating in the discussion groups recommended the EORTC-QLQ-C30 as the PROM covering most of these variables' (line 200). This view was then used to design the Delphi questionnaire, yet it is noteworthy that only 4 haematologists and 4 pharmacists took part in these groups (line 100). It is hard to interpret the relatability of this recommendation without more detail on the methods used to support these 8 professionals in selecting the best PROM for appraisal in the Delphi phase. A clear description is included of why these professionals chose to exclude the EORTC MY20 myeloma module (line 205), but there are other myeloma-specific tools that were not mentioned: Were these identified and appraised by the discussion groups? Were patients involved in this appraisal? What were their conclusions? This detail is central to interpreting the relatability of the study findings the authors' subsequent conclusions.
R1A6: As explained above, the variables and instrument selection process has been described more in detail in Methods.
Line 94 (Methods: literature review)
Health professionals of discussion groups considered that the EORTC-QLQ-C30 provides the essential information and is more used in routine clinical practice than the myeloma-specific tools. This has been discussed in the manuscript.
Line 213 (Results: Patient Reported Outcomes and Patient Reported Experiences: PROs) "The expert participants in the discussion groups were aware that questionnaires such as QLQ-MY20 module [18] or include questions that specifically target MM aspects. However, trying to balance feasibility of use in routine clinical practice and essential information, the use of the EORTC-QLQ-C30 questionnaire alone was considered the best balanced choice. Since EORTC-QLQ-C30 is also used for other type of cancer, health professionals considered that its implementation in routine clinical practice would be simpler."
MyPOS questionnaire, in particular, was previously discarded by the scientific committee since a Spanish validated version is not available.
